Hironobu Sou

Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging

PURPOSE To describe imaging findings of early hepatocellular carcinoma (HCC) at gadoxetic acid-enhanced magnetic resonance (MR) imaging, dynamic contrast material-enhanced computed tomography (CT), CT during arterial portography (CTAP), and CT during hepatic arteriography (CTHA) and to compare the diagnostic performance of each modality for small (≤ 2 cm) HCC. MATERIALS AND METHODS The institute ethics committee deemed study approval unnecessary. One hundred eight resected small lesions in 64 patients were diagnosed as a dysplastic nodule (DN) (n = 12), progressed HCC (n = 66), or early HCC (n = 30). All but two patients underwent all imaging examinations. The imaging characteristics of the lesions with each modality were determined. To evaluate the diagnostic performance of the modalities, two radiologists graded the presence of HCC with use of a five-point confidence scale. The area under the receiver operating characteristic curve (A(z)), sensitivity, and specificity of each modality were compared. RESULTS The imaging features that are statistically significant for differentiating an early HCC from a DN include fat-containing lesions at dual-echo T1-weighted MR imaging (seen in 16 of the 30 early HCCs and none of the DNs), low attenuation at unenhanced CT (seen in 13 of the 30 early HCCs and none of the DNs), low attenuation at CTAP (seen in 11 of the 30 early HCCs and none of the DNs), and low signal intensity at hepatocyte phase gadoxetic acid-enhanced MR imaging (seen in 29 of the 30 early HCCs and none of the DNs). The diagnostic performance of gadoxetic acid-enhanced MR imaging (A(z), 0.98 and 0.99) was significantly greater than that of contrast-enhanced CT (A(z), 0.87) and CTHA-CTAP (A(z), 0.85 and 0.86) owing to its significantly higher sensitivity (P < .001). CONCLUSION Gadoxetic acid-enhanced MR imaging is the most useful imaging technique for evaluating small HCC, including early HCC.

High-b Value Diffusion-Weighted MRI for Detecting Pancreatic Adenocarcinoma: Preliminary Results

OBJECTIVE The objective of our study was to evaluate the usefulness of high-b value diffusion-weighted MRI (DWI) in the detection of pancreatic adenocarcinoma. SUBJECTS AND METHODS Twenty-six patients with pancreatic adenocarcinoma were included in the study. Twenty-three other patients who were being followed up due to pancreatic diseases other than adenocarcinoma were included as control subjects. All patients and subjects underwent DWI, and the images were evaluated by three blinded radiologists. RESULTS Receiver operating characteristic (ROC) curve analysis yielded A(z) values (i.e., area under the ROC curve) of 0.998, 0.998, and 0.995 for the three radiologists. The mean sensitivity and specificity for the detection of pancreatic adenocarcinoma were 96.2% and 98.6%, respectively. The kappa values indicating interobserver agreement between different pairs of radiologists were in the category of excellent. CONCLUSION High-b value DWI allows the detection of pancreatic adenocarcinoma with a high sensitivity and specificity.

High-B-value diffusion-weighted MRI in colorectal cancer.

OBJECTIVE The purpose of this article is to evaluate the usefulness of high-b-value diffusion-weighted MRI (DW-MRI) in the detection of colorectal adenocarcinoma. CONCLUSION High-b-value DW-MRI allows detection of colorectal adenocarcinoma with a high sensitivity and specificity.

Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?

To clarify the factors that predict enhancement of the liver parenchyma in hepatocyte‐phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd‐EOB‐DTPA)‐enhanced MR imaging.

Distinguishing Hypervascular Pseudolesions of the Liver from Hypervascular Hepatocellular Carcinomas with Gadoxetic Acid-enhanced MR Imaging

PURPOSE To retrospectively determine findings at gadoxetic acid-enhanced magnetic resonance (MR) imaging in hypervascular pseudolesions that were observed at computed tomography (CT) during hepatic arteriography, with special focus on distinguishing these pseudolesions from hypervascular hepatocellular carcinomas (HCCs). MATERIALS AND METHODS The institute ethics committee deemed study approval unnecessary. The study population comprised 80 patients (55 men, 25 women) with chronic liver disease who underwent CT during hepatic arteriography and arterial portography, gadoxetic acid-enhanced MR imaging, and follow-up dynamic contrast material-enhanced CT. The diagnosis of 104 pseudolesions and 123 HCCs was confirmed by means of histopathologic or multimodality evaluation. Two radiologists assessed the MR imaging findings of HCCs and pseudolesions in consensus, including the signal intensities (SIs) of the lesions on T2-weighted, diffusion-weighted (DW), and contrast-enhanced hepatocyte-phase images. The findings of nodular pseudolesions and HCCs were compared with the Fisher exact test. Additionally, the hepatocyte-phase SI ratio (ratio of lesion SI to liver SI) for HCCs and pseudolesions was compared by means of the Mann-Whitney U test. RESULTS There were 62 wedge-shaped, 32 nodular, and 10 linear pseudolesions. On gadoxetic acid-enhanced hepatocyte-phase MR images, 15% of pseudolesions (16 of 104) were hypointense compared with surrounding liver tissue. The mean hepatocyte-phase SI ratio of HCCs (0.65 +/- 0.14 [standard deviation]) was significantly lower (P < .01) than that of the nodular pseudolesions (0.95 +/- 0.11). The optimal cutoff value of hepatocyte-phase SI ratio for distinguishing between HCC and nodular pseudolesion was 0.84. No nodular pseudolesions were visible on DW images. CONCLUSION Gadoxetic acid-enhanced hepatocyte-phase MR imaging and DW imaging could be used to distinguish hypervascular pseudolesions from hypervascular HCCs; a hepatocyte-phase SI ratio below 0.84 and visibility on DW images were findings specific for HCCs rather than pseudolesions.

Diagnosis of colorectal hepatic metastases: Comparison of contrast‐enhanced CT, contrast‐enhanced US, superparamagnetic iron oxide‐enhanced MRI, and gadoxetic acid‐enhanced MRI

To compare the diagnostic accuracy of contrast‐enhanced computed tomography (CE‐CT), contrast‐enhanced ultrasonography (CE‐US), superparamagnetic iron oxide‐enhanced magnetic resonance imaging (SPIO‐MRI), and gadoxetic acid‐enhanced MRI (Gd‐EOB‐MRI) in the evaluation of colorectal hepatic metastases.

Detection of Pancreatic Carcinoma and Liver Metastases with Gadoxetic Acid–enhanced MR Imaging: Comparison with Contrast-enhanced Multi–Detector Row CT

PURPOSE To intraindividually compare gadoxetic acid-enhanced magnetic resonance (MR) imaging with contrast material-enhanced multi-detector row computed tomography (CT) in detection of pancreatic carcinoma and liver metastases. MATERIALS AND METHODS The ethics committee approved this retrospective study with waiver of informed consent. This study included 100 patients (53 men, 47 women; mean age, 67.8 years) consisting of 54 patients with pathologically confirmed pancreatic carcinoma (mean size, 33 mm) and 46 without a pancreatic lesion. Sixty-two liver metastases (mean size, 10 mm) in 15 patients with pancreatic carcinoma were diagnosed at pathologic examination or multimodality assessment. Three readers blinded to the final diagnosis interpreted all MR (precontrast T1- and T2-weighted and gadoxetic acid-enhanced dynamic and hepatocyte phase MR images) and tetraphasic dynamic contrast-enhanced CT images and graded the presence (or absence) of pancreatic carcinoma and liver metastasis on patient-by-patient and lesion-by-lesion bases. Receiver operating characteristic analysis, McNemar test, and Fisher test were performed to compare the diagnostic performance of CT and MR imaging. RESULTS No significant differences were observed between CT and MR images in depiction of pancreatic carcinoma. However, MR imaging had greater sensitivity in depicting liver metastasis than did CT for two of the three readers in the MR imaging-versus-CT analysis (85% vs 69%, P = .046) and for all three readers in the lesion-by-lesion analysis (92%-94% vs 74%-76%, P = .030-.044). CONCLUSION Gadoxetic acid-enhanced MR imaging was equivalent to dynamic contrast-enhanced CT in depicting pancreatic carcinoma and had better sensitivity for depicting liver metastases, suggesting the usefulness of gadoxetic acid-enhanced MR imaging for evaluation of patients with pancreatic carcinoma.

Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.

To elucidate the natural history of hypovascular nodules that appear hypointense on hepatocyte‐phase gadoxetic acid‐enhanced MR images by focusing on hypervascularization over time.

Diffusion-Weighted MR Imaging in the Evaluation of Pancreatic Exocrine Function Before and After Secretin Stimulation

OBJECTIVES: To evaluate diffusion weighted MR imaging before and after secretin stimulation in the assessment of pancreatic exocrine function in the setting of chronic pancreatitis.METHODS: Nine patients with severe chronic pancreatitis and sixteen patients without chronic pancreatitis but with a history of chronic alcohol consumption were enrolled in the chronic pancreatitis and risk groups, respectively. Thirty-eight patients without any pancreatic disease or history of alcohol consumption were included in the control group. Diffusion weighted images were obtained before and after secretin administration in all patients. The peak ADC values and times were determined and intergroup differences were compared. A receiver operating characteristic curve (ROC) was used to identify the cutoff values of the peak ADC times for discrimination of control group from risk and chronic pancreatitis groups.RESULTS: In the control group, a peak increase in ADC value of 57–120% (median: 75%) was observed between 90 s and 4 min (median: 2 min) after administration of secretin (Pattern 1). In the risk group, in 13 patients, a peak increase of 52–150% was observed between 4 and 8 min (median: 7 min; Pattern 2). Peak times were significantly longer in risk group (p < 0.01). In three patients in the risk group, and in all patients in the chronic pancretitis group, no ADC peak was observed within 10 min following secretin administration (Pattern 3). Using a peak time of 4 min as the cut-off value, a sensitivity of 100% and specificity of 94.7% were achieved in discriminating the control group from the combined risk and chronic pancreatitis groups.CONCLUSION: Diffusion-weighted MR imaging before and after secretin administration could yield clinically useful information for detecting pathophysiologic alterations in the setting of chronic pancreatitis.

Diagnosis of Peritoneal Dissemination: Comparison of 18F-FDG PET/CT, Diffusion-Weighted MRI, and Contrast-Enhanced MDCT

OBJECTIVE The purpose of this study was to compare the diagnostic performance of (18)F-FDG PET/CT, MRI with and without diffusion-weighted imaging (DWI), and contrast-enhanced MDCT in the detection of peritoneal dissemination of malignant tumors. MATERIALS AND METHODS We retrospectively evaluated the cases of 107 patients who underwent PET/CT and 130 patients who underwent MRI and contrast-enhanced MDCT. Twenty-six patients who underwent PET/CT and 23 who underwent MRI and contrast-enhanced MDCT were found to have peritoneal dissemination. All images were independently evaluated by two radiologists using a 5-point grading system. The results of PET/CT, T1- and T2-weighted MRI without DWI, MRI with DWI (b = 1,000 s/mm(2)), and contrast-enhanced MDCT were compared patient by patient and lesion by lesion by use of receiver operating characteristics analysis. Sensitivity, specificity, and positive predictive value were calculated and compared by use of the chi-square test. RESULTS Patient by patient, the area under the receiver operating characteristics curve of MRI without DWI (0.88) was significantly less than that of the other modalities (contrast-enhanced MDCT, 0.91; MRI with DWI, 0.93; PET/CT, 0.97). The sensitivity of PET/CT (94%) was significantly higher than that of MRI without DWI (70%). The specificities of the modalities were not significantly different. In lesion-by-lesion analysis, MRI without DWI had significantly lower sensitivity (56%) than the other modalities (contrast-enhanced MDCT, 76%; MRI with DWI, 84%; PET/CT, 89%). The positive predictive value of PET/CT (93%) was significantly higher than that of the other three modalities (contrast-enhanced MDCT, 73%; MRI without DWI, 70%; MRI with DWI, 72%). CONCLUSION PET/CT is the most useful technique for pathologic staging in the care of patients with malignant disease. If PET/CT is not available, DWI can be used as a screening tool.